The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’

‘Compliance With Sustainability Goals Must Not Give Rise To Unintended Consequences ‘

Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.

Shutterstock

“Rethinking what we’ve traditionally done as an industry.” That is the big picture view that encapsulates how Meron Mathias sees her role as vice president, CSR and sustainability, at Thermo Fisher Scientific.

Adjusting the company’s environmental footprint to enable it – and its entire value chain ̶ to meet the carbon zero...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

Vigya test infogram - Clone

add a desc test

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Vigya test infogram

add a desc test

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.